Hetrombopag + Matching placebo
Phase 3Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Thrombocytopenia
Conditions
Chemotherapy-Induced Thrombocytopenia
Trial Timeline
Apr 15, 2022 → Dec 15, 2025
NCT ID
NCT05261646About Hetrombopag + Matching placebo
Hetrombopag + Matching placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Chemotherapy-Induced Thrombocytopenia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05261646. Target conditions include Chemotherapy-Induced Thrombocytopenia.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Thrombocytopenia were approved
Approved (3) Terminated (3) Active (15)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05261646 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Chemotherapy-Induced Thrombocytopenia